natgillin/translations-raw huggingface dataset:
ORENCIA powder for concentrate for solution for infusion is a white to off-white powder that can appear solid or broken into pieces.
ORENCIA prašak za koncentrat za otopinu za infuziju je bijeli do bjelkasti prašak, koji može biti cjelovit ili razlomljen na komadiće.
ORENCIA SC PATIENT ALERT CARD TEXT
TEKST KARTICE ZA BOLESNIKA S UPOZORENJIMA O LIJEKU ORENCIA ZA POTKOŽNU PRIMJENU
ORENCIA selectively modulates the activation of T cells involved in the immune systems’ inflammatory response.
ORENCIA selektivno modulira aktiviranje T-stanica uključenih u upalni odgovor imunološkog sustava.
ORENCIA should be administered as a 30-minute intravenous infusion.
ORENCIA se primjenjuje u obliku 30-minutne intravenske infuzije.
ORENCIA should not be used with biological medicines for rheumatoid arthritis, including TNF- blockers like adalimumab, etanercept, and infliximab; there is not enough evidence to recommend its being given with anakinra and rituximab.
ORENCIA se ne smije primjenjivati zajedno s biološkim lijekovima za liječenje reumatoidnog artritisa, uključujući TNF-blokatore kao što su adalimumab, etanercept i infliksimab; nema dovoljno dokaza da bi se mogla preporučiti istodobna primjena s anakinrom i rituksimabom.
ORENCIA solution for injection (injection) is a clear, colourless to pale yellow solution provided in a pre-filled pen called ClickJect.
ORENCIA otopina za injekciju (injekcija) je bistra, bezbojna do blijedožuta otopina koja dolazi u napunjenoj brizgalici naziva ClickJect.
ORENCIA solution for injection (injection) is a clear, colourless to pale yellow solution.
ORENCIA otopina za injekciju (injekcija) je bistra, bezbojna do blijedožuta otopina.
ORENCIA solution for injection has not been studied in children and adolescents under the age of 18 years.
ORENCIA otopina za injekciju nije ispitivana u djece i adolescenata mlađih od 18 godina.
ORENCIA solution for injection is injected under the skin (subcutaneous use).
ORENCIA otopina za injekciju injicira se pod kožu (potkožna primjena).
ORENCIA, in combination with methotrexate, is indicated for: the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor. the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.
ORENCIA je, u kombinaciji s metotreksatom, indicirana za: liječenje umjerenog do teškog oblika aktivnog reumatoidnog artritisa (RA) u odraslih bolesnika koji nisu dovoljno dobro odgovorili na prethodnu terapiju jednim ili više lijekova koji modificiraju tijek bolesti (engl. disease-modifying anti-rheumatic drugs, DMARD), uključujući metotreksat (MTX) ili inhibitor faktora nekroze tumora (TNF)-alfa. liječenje izrazito aktivne i progresivne bolesti u odraslih bolesnika s reumatoidnim artritisom koji prethodno nisu bili liječeni metotreksatom.
oreness and swelling of the digestive tract lining which runs from the mouth to the anus (mucosal inflammation)
bolnost i oticanje sluznice probavnog trakta koja ide od usta do čmara (upala sluznice)
oreness and swelling of the digestive tract lining which runs from the mouth to the anus (mucosal inflammation)
bolnost i otok sluznice probavnog trakta koja se proteže od usta do čmara (upala sluznice)
oreness and swelling of the digestive tract lining which runs from the mouth to the anus (mucosal inflammation)
bolovi i oticanje sluznice probavnog sustava od usta do anusa (upala sluznice/mukozitis)
ores in mouth, scaling lips and clefts in the corners of the mouth, rash, redness of skin, itching, eczema (inflamed, red, itchy and dryness of the skin with possible oozing lesions), acne, back pain, muscle and bone pain, limb pain, dryness, pain, rash, irritation or itching at the site of injection.
ranice u ustima, ljuštenje usana i pucanje kutova usana, osip, crvenilo kože, svrbež, ekcem (upaljena, crvena, suha koža koja svrbi, ponekad s oštećenjima iz kojih se cijedi tekući sadržaj), akne, bol u leđima, mišićno-koštana bol, bol u udovima, suhoća, bol, osip, iritacija ili svrbež na mjestu injekcije.
ores in the mouth
ranice u ustima
ores in the mouth and the tube from the mouth to the stomach, which may be painful and cause difficulty swallowing,
ranice u ustima i jednjaku koje mogu biti bolne i uzrokovati poteškoće pri gutanju,
ores or ulcers in the mouth, diarrhoea, stomach pain, heartburn, difficulty swallowing, dry mouth
rane ili ulceracije u ustima, proljev, bol u želucu ili trbuhu, žgaravica, otežano gutanje, suha usta
Orfadin 2 mg hard capsules Orfadin 5 mg hard capsules Orfadin 10 mg hard capsules Orfadin 20 mg hard capsules Nitisinone
Orfadin 2 mg tvrde kapsule Orfadin 5 mg tvrde kapsule Orfadin 10 mg tvrde kapsule Orfadin 20 mg tvrde kapsule nitizinon
Orfadin is also available in 2 mg, 5 mg, 10mg and 20 mg capsules, if considered more suitable for the patient.
Orfadin je također dostupan u kapsulama od 2 mg, 5 mg 10 mg i 20 mg, ako se smatraju pogodnijima za bolesnika.
Orfadin was originally authorised under ‘exceptional circumstances’, because, as the disease is rare, limited information was available at the time of the approval.
Orfadin je prvobitno odobren u „iznimnim okolnostima” zbog toga što su, iz znanstvenih razloga, u trenutku izdavanja odobrenja bile dostupne samo ograničene informacije.
Orgalutran and FSH should be administered approximately at the same time.
Orgalutran i FSH treba davati približno u isto vrijeme.
Orgalutran contains less than 1 mmol sodium (23 mg) per injection, i.e. essentially ‘sodium-free’.
Orgalutran sadrži manje od 1 mmol natrija (23 mg) po injekciji, tj. zanemarive količine natrija.
Orgalutran contains sodium
Orgalutran sadrži natrij
Orgalutran contains the active substance ganirelix and belongs to a group of medicines called “anti- gonadotrophin-releasing hormones” which act against the actions of the natural gonadotrophin releasing hormone (GnRH).
Orgalutran sadrži djelatnu tvar ganireliks i pripada skupini lijekova koji se zovu "antagonisti gonadotropin-oslobađajućeg hormona", a koji sprječavaju djelovanje prirodnog gonadotropin-oslobađajućeg hormona (GnRH).
Orgalutran is a clear and colourless aqueous solution for injection.
Orgalutran je bistra i bezbojna vodena otopina za injekciju.
Orgalutran is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitive binding to the GnRH receptors in the pituitary gland.
Orgalutran je antagonist GnRH-a, koji modulira os hipotalamus-hipofiza-gonade kompetitivnim vezanjem na receptore GnRH-a u hipofizi.
Organ Class
Organski sustav
Organ function impairment
Oštećenje funkcije bubrega
Organ growth: Growth hormone increases the size of internal organs, including kidneys, and increases red blood cell mass.
Rast organa: Hormon rasta povećava veličinu unutarnjih organa, uključujući i bubrege kao i masu eritrocita.
organ or bone marrow transplant, for psoriasis or eczema, or for rheumatoid arthritis or nephrotic syndrome)
e, npr. nakon presađivanja organa ili koštane srži, kod psorijaze ili ekcema ili reumatoidnog artritisa ili nefrotskog sindroma)
Organ systems
Organski sustavi
Organ transplant
Presađeni organi
Organ transplant patients
Bolesnici s presađenim organima
Organ transplant patients
Bolesnici s transplantiranim organima
Organ transplant recipients
Primatelji presatka organa
Organ uptake
Nakupljanje u organima
Organ uptake
Unos u organe
Organ/System (Frequency)
Organ/Sustav (Učestalost)
Organic anion transporting polypeptide (OATP) inhibitors
Inhibitori polipeptidnih transportera organskih aniona (OATP)
Organic anion transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are involved in MPA’s disposition; OATP isoforms, MRP2 and breast cancer resistance protein (BCRP) are transporters associated with the glucuronides’ biliary excretion.
U raspoloživosti MPA sudjeluju organski anionski transportni polipeptidi (engl. organic anion-transporting polypeptide, OATP) i protein povezan s rezistencijom na više lijekova 2 (engl. multidrug resistance-associated protein 2, MRP2); izooblici OATP-a, MRP2 i protein koji uzrokuje rezistenciju raka dojke na lijekove (engl. breast cancer resistance protein, BCRP) prijenosnici su povezani s izlučivanjem tih glukuronida kroz žuč.
Organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are involved in MPA’s disposition; OATP isoforms, MRP2 and breast cancer resistance protein (BCRP) are transporters associated with the glucuronides’ biliary excretion.
U raspoloživosti MPA sudjeluju organski anionski transportni polipeptidi (engl. organic anion-transporting polypeptide, OATP) i protein povezan s rezistencijom na više lijekova 2 (engl. multidrug resistance-associated protein 2, MRP2); izooblici OATP-a, MRP2 i protein koji uzrokuje rezistenciju raka dojke na lijekove (engl. breast cancer resistance protein, BCRP) prijenosnici su povezani s izlučivanjem tih glukuronida kroz žuč.
Organisation of home infusion/preparation of infusion;
organizacija primjene infuzije kod kuće/priprema infuzije;
Organisation: Home environment/Caregiver/Treating physician;
organizacijiske uvjete liječenja: kućno okruženje/njegovatelj/nadležni liječnik;
Organism group
Skupina organizama
Organisms that express these enzymes and which are therefore resistant to ceftaroline occur at very variable rates between countries and between healthcare facilities within countries.
Organizami koji proizvode te enzime te su stoga rezistentni na ceftarolin pojavljuju se u vrlo različitim stopama od zemlje do zemlje kao i između zdravstvenih ustanova u istoj zemlji.
Organon (Ireland) Limited Drynam Road
Proizvođač Organon (Ireland) Limited Drynam Road
Orgasm abnormal Abnormal dreams
abnormalni orgazam abnormalni snovi
Orgasm abnormal Abnormal dreams
uicidalne misli5,7
orientation, depression, anxiety symptoms, hallucination, mental disorders, depressed mood, mood disorders and disturbances, nightmare
dezorijentacija, depresija, simptomi anksioznosti, halucinacije, mentalni poremećaji, depresivno raspoloženje, poremećaji i smetnje raspoloženja, noćne more
Oriented polyamide (OPA)-aluminium-polyvinyl chloride (PVC)/aluminium push-through layer.
Orijentirani poliamid (OPA)-aluminij-polivinilklorid (PVC)/aluminij protisni sloj.
Orifarm Generics AB Tel: +46 40 680 02 60
Orifarm Generics AB Tel: + 40 680 02 30
Origin
Izvor
original dose and tacrolimus
jednu trećinu prijašnje doze i
Original study and
Prvotno ispitivanje i terapijska skupina
Original study and treatment group
Prvotno ispitivanje i terapijska skupina
Originally reported terms have been coded to preferred terms (using the Medical Dictionary for Regulatory Activities [MedDRA]).
Izvorno prijavljeni pojmovi su kodirani na preporučene pojmove (koristeći Medicinski rječnik za regulatorne poslove [MedDRA]).
Originally, in 3 studies (one comparative vs fluconazole, two non-comparative) 204 patients were studied; the mean duration of intravenous treatment in these patients was 13.5 days (range, 1 to 38 days) and 119 patients received ≥ 14 days of anidulafungin.
Izvorno su u tri ispitivanja (jedno usporedno s flukonazolom i dva neusporedna) proučavana 204 bolesnika; intravensko liječenje u ovih bolesnika prosječno je trajalo 13,5 dana (raspon, 1 do 38 dana), a 119 bolesnika primalo je anidulafungin ≥ 14 dana.
Orion Corporation Orion Pharma Orionintie 1
Orion Corporation, Orion Pharma Orionintie 1
ORION CORPORATION P.O.Box 65
Orion OYJ Ružová dolina 6,
Orion Corporation Tel: + +358 10 4261
Orion Corporation Tel: +358 10 4261
Orion OYJ Ružová dolina 6,
FI-02101, Espoo, Finland Predstavnik:
Orion Pharma Animal Health Tel: +46 (0) 8 623 6440
Tel: +46 (0) 8 623 6440
orised orised
pumpica od 215 µl
Oritavancin concentrations achieved in the blood after 1200 mg doses may produce falsely elevated results from certain laboratory tests (see Table 1).
Koncentracije oritavancina dostignute u krvi nakon doza od 1200 mg mogu proizvesti lažno povišene vrijednosti kod određenih laboratorijskih testova (vidjeti Tablicu 1).
Oritavancin concentrations that are found in the blood of patients following administration of a single dose have been shown to artificially prolong: aPTT for up to 120 hours,
Koncentracije oritavancina koje su pronađene u krvi bolesnika nakon primjene jedne doze pokazale su da umjetno produljuju: aPTV tijekom 120 sati
Oritavancin exhibits reduced in vitro activity against certain Gram-positive organisms of the genera
Oritavancin pokazuje smanjenu aktivnost in vitro protiv određenih gram-pozitivnih organizama rodova
Oritavancin has been shown to artificially prolong prothrombin time (PT) and international normalised ratio (INR) for up to 12 hours, making the monitoring of the anticoagulation effect of warfarin unreliable up to 12 hours after an oritavancin dose.
Uočeno je da oritavancin umjetno produljuje protrombinsko vrijeme (PV) i međunarodni normalizirani omjer (INR) do 12 sati, što čini praćenje antikoagulacijskog učinka varfarina nepouzdanim do12 sati nakon doze oritavancina.
Oritavancin has been shown to cause infusion related reactions including pruritus, urticaria or flushing.
Uočeno je da oritavancin može prouzročiti reakcije povezane s infuzijom, uključujući svrbež, urtikariju ili crvenilo uz osjećaj vrućine.
Oritavancin is a type of antibiotic (a lipoglycopeptide antibiotic) that can kill or stop the growth of certain bacteria.
Oritavancin je vrsta antibiotika (lipoglikopeptidni antibiotik) koji može ubiti ili zaustaviti rast određenih bakterija.
Oritavancin is active against Gram positive bacteria only (see section 5.1).
Oritavancin je aktivan samo protiv gram-pozitivnih bakterija (vidjeti dio 5.1.).
Oritavancin was found to be a nonspecific, weak inhibitor (CYP2C9 and CYP2C19) or a weak inducer (CYP3A4 and CYP2D6) of several CYP isoforms.
Oritavancin se pokazao nespecifičnim, slabim inhibitorom (CYP2C9 i CYP2C19) ili slabim induktorom (CYP3A4 i CYP2D6) nekoliko CYP izoformi.
Orkambi 200 mg/125 mg film-coated tablets lumacaftor/ivacaftor
Orkambi 200 mg/125 mg filmom obložene tablete lumakaftor/ivakaftor
Orkambi 200 mg/125 mg tablets lumacaftor/ivacaftor
Orkambi 200 mg/125 mg tablete lumakaftor/ivakaftor
Orkambi can only be prescribed by a doctor with experience in the treatment of cystic fibrosis.
Orkambi može propisati samo liječnik koji je iskusan u liječenju cistične fibroze.
Orkambi contains two active substances, lumacaftor and ivacaftor that work together to improve the function of the abnormal CFTR protein.
Orkambi sadrži dvije djelatne tvari, lumakaftor i ivakaftor, koje zajedno djeluju kako bi poboljšale funkciju abnormalnog proteina CFTR.
Orkambi has no or negligible influence on the ability to drive or use machines.
Orkambi ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Orkambi has no or negligible influence on the ability to drive or use machines.
Orkambi ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i strojevima.
Orkambi is a medicine used for long-term treatment of cystic fibrosis (CF) in patients aged 12 years and older who have a specific change (called F508del mutation) affecting the gene for a protein called cystic fibrosis transmembrane conductance regulator (CFTR), which plays an important role in regulating the flow of mucus in the lungs.
Orkambi je lijek koji se primjenjuje za dugoročno liječenje cistične fibroze u bolesnika u dobi od 12 i više godina sa specifičnom promjenom (zvanom mutacija F508del) koja utječe na gen za protein pod nazivom transmembranski regulator provodljivosti u cističnoj fibrozi (engl. skraćeno CFTR), koji igra važnu ulogu u regulaciji protoka sluzi u plućima.
Orkambi is a medicine used to treat cystic fibrosis in patients aged 12 years and above who have a genetic mutation called the F508del mutation.
Orkambi je lijek koji se primjenjuje za liječenje cistične fibroze u bolesnika u dobi od 12 i više godina s genetičkom mutacijom zvanom mutacija F508del.
Orkambi is available as tablets containing 200 mg lumacaftor and 125 mg ivacaftor.
Orkambi je dostupan u obliku tableta od 200 mg lumakaftora i 125 mg ivakaftora.
Orkambi is available in the following pack sizes: Pack size of 112 tablets (4 packs of 28 tablets each).
Orkambi je dostupan u sljedećim veličinama pakiranja: Pakiranje od 112 tableta (4 pakiranja po 28 tableta).
Orkambi is to be taken by mouth.
Orkambi se uzima kroz usta.
Orkambi is used in patients who have inherited the mutation from both parents and therefore have the mutation in both copies of the CFTR gene.
Orkambi se primjenjuje u bolesnika koji su naslijedili mutaciju od oba roditelja i stoga imaju mutaciju obje kopije gena CFTR.
Orkambi lumacaftor / ivacaftor
Orkambi lumakaftor/ivakaftor
Orkambi was shown to be effective at improving lung function in two main studies involving 1,108 cystic fibrosis patients aged 12 years and above who had the F508del mutation in both copies of the CFTR gene.
Dva glavna ispitivanja provedena na 1 108 bolesnika s cističnom fibrozom u dobi od 12 i više godina s mutacijom F508del u obje kopije CFTR gena pokazala su da je Orkambi djelotvoran pri poboljšanju plućne funkcije.
Orkambi’s side effects mainly affected the gut and breathing and were generally considered mild to moderate and manageable.
Nuspojave lijeka Orkambi uglavnom su utjecale na probavni sustav i disanje te se smatralo da su općenito blage do umjerene i da ih se može kontrolirati.
Orlistat has no or negligible influence on the ability to drive and use machines.
Orlistat nema utjecaj ili ima zanemariv utjecaj na sposobnost upravljanja vozilima i strojevima.
Orlistat may decrease the absorption of antiepileptic medicinal products, leading to convulsions.
Orlistat može smanjiti apsorpciju antiepileptika, što pak može dovesti do konvulzija.
Orlistat may potentially reduce the absorption of antiretroviral medicines for HIV and could negatively affect the efficacy of antiretroviral medications for HIV (see section 4.5).
Orlistat može potencijalno smanjiti apsorpciju antiretrovirusnih lijekova za liječenje HIV-a te može imati negativan utjecaj na učinkovitost antiretrovirusnih lijekova za liječenje HIV-a (vidjeti odjeljak 4.5).
Orlistat, M1 and M3 are all subject to biliary excretion.
Orlistat, M1 i M3, izlučuju se putem žuči.
Orodispersible
Raspadljiva tableta
Orodispersible tablet
Raspadljiva
Orodispersible tablet
Raspadljiva tableta
Orodispersible tablet
Raspadljiva tableta za usta.
Orodispersible tablet is the technical name for a tablet which dissolves directly in your mouth, so that it can be easily swallowed.
Raspadljiva tableta za usta tehnički je naziv za tabletu koja se otapa izravno u ustima, tako da se može lako progutati.
Orodispersible tablets are round and white tablets.
Raspadlive tablete za usta su okrugle i bijele.
Orodispersible tablets or oral solution may be used as an alternative to Aripiprazole Sandoz tablets for patients who have difficulty swallowing Aripiprazole Sandoz tablets (see section 5.2).
Raspadljive tablete za usta ili oralna otopina mogu se primjenjivati kao zamjena za Aripiprazol Sandoz tablete u bolesnika kojima je teško progutati Aripiprazol Sandoz tablete (vidjeti dio 5.2).
Orodispersible tablets:
Raspadljive tablete za usta:
Oromucosal gel
Gel za usnu sluznicu
Oromucosal gel.
Gel za usnu sluznicu.
Oromucosal solution
Otopina za usnu sluznicu
Oromucosal solution Clear colourless solution pH 2.9 to 3.7
Otopina za usnu sluznicu Bistra, bezbojna otopina pH 2,9 do 3,7
Oromucosal solution pre-filled oral syringes
Otopina za usnu sluznicu napunjene štrcaljke za usta
Oromucosal spray
Sprej za usnu sluznicu
Oromucosal use
Za usnu sluznicu
Oromucosal use
Za usnu sluznicu.
Oromucosal use.
Za usnu sluznicu.
Oropharyngeal candidiasis
Kandidijaza usta i ždrijela
Oropharyngeal pain
Bol u ustima i ždrijelu
Oropharyngeal pain
bol u ždrijelu
Oropharyngeal pain
Bol usta i ždrijela
Oropharyngeal pain
orofaringaelna bol
Oropharyngeal pain
Orofaringe alna bol
Oropharyngeal pain
orofaringealna bol
Oropharyngeal pain
orofaringealni bol
Oropharyngeal pain including throat irritation Common
Orofaringealna bol uključujući nadražaj grla Često
Oropharyngeal pain including throat irritation2
Orofaringealna bol uključujući nadražaj grla2
Oropharyngeal pain Rhinorrhoea
orofaringealna bol rinoreja
Oropharyngeal pain, Nasal congestion, Cough
bol u ždrijelu i grkljanu, nazalna kongestija, kašalj
oropharyngeal pain, sneezing, cough, postnasal drip, throat irritation
orofaringealna bol, kihanje, kašalj, sekrecija iz nosa u ždrijelo, nadraženo grlo
Oropharyngeal paina
orofaringealna bola
Oropharyngeal pain†
Orofaringealna bol
Oropharyngeal spasm Laryngospasm Aspiration pneumonia
orofaringealni spazam, laringospazam, aspiracijska pneumonija
Oropharyngeal swelling
oticanje orofarinksa
Orphacol 250 mg capsules cholic acid
Orphacol 250 mg kapsule kolatna kiselina
Orphacol 250 mg hard capsules cholic acid
Orphacol 250 mg tvrde kapsule kolatna kiselina
Orphacol 250 mg: Each hard capsule contains 250 mg of cholic acid.
Orphacol 250 mg: svaka tvrda kapsula sadrži 250 mg kolatne kiseline.
Orphacol 250 mg: gelatin, titanium dioxide (E171), carmine blue (E132), yellow iron oxide (E172).
Orphacol 250 mg: želatina, titanijev dioksid (E171), tamno plava (E132), žuti željezov oksid (E172).
Orphacol 50 mg capsules cholic acid
Orphacol 50 mg kapsule kolatna kiselina
Orphacol 50 mg hard capsules cholic acid
Orphacol 50 mg tvrde kapsule kolatna kiselina
Orphacol 50 mg hard capsules Orphacol 250 mg hard capsules cholic acid
Orphacol 50 mg tvrde kapsule Orphacol 250 mg tvrde kapsule kolatna kiselina
Orphacol 50 mg: Each hard capsule contains 50 mg of cholic acid.
Orphacol 50 mg: svaka tvrda kapsula sadrži 50 mg kolatne kiseline.
Orphacol 50 mg: gelatin, titanium dioxide (E171), carmine blue (E132);
Orphacol 50 mg: želatina, titanijev dioksid (E171), tamno plava (E132);
Orphacol has been authorised under ‘exceptional circumstances’.
Orphacol je odobren pod „iznimnim okolnostima”.
Orphacol is hard capsules (capsules) of oblong shape.
Orphacol su tvrde kapsule (kapsule) duguljastog oblika.
Orphan Europe (Germany) GmbH Eberhard-Finckh-Straße 55
Orphan Europe (Germany) GmbH Max-Planck Str.
Orphan Europe (Germany) GmbH Tel: +49 731 140 554 0
Orphan Europe (Germany) GmbH Tel : +49 731 140 554 0
Orphan Europe (Italy) Srl Via Marostica, 1
Orphan Europe (Italy) Srl Via Cellini 11
Orphan Europe AB Isafjordsgatan 30C, plan 3 S-164 40 Kista
Orphan Europe AB Banérgatan 37
Orphan Europe AB Simi:+46 8 545 80 230
Orphan Europe AB Sími: +46 8 545 80 230
Orphan Europe AB Tel: + 46 8 545 80 230
Orphan Europe AB Tel : +46 8 545 80 230
Orphan Europe AB Tlf : +46 8 545 80 230
Orphan Europe AB Tlf :+46 8 545 80 230
Orphan Europe Benelux Koning Albert I Iaan 48 bus 3 BE-1780 Wemmel (Brussels) België
Orphan Europe Benelux Koning Albert I laan 48 bus 3 BE-1780 Wemmel (Brussels) België
Orphan Europe S.A.R.L Immeuble “Le Wilson”
Orphan Europe SARL Immeuble “Le Wilson”
Orphan Europe SARL Immeuble "Le Wilson"
Orphan Europe S.A.R.L. Immeuble "Le Wilson"
Orphan Europe SARL Immeuble "Le Wilson"
Orphan Europe SARL, Immeuble “Le Wilson”
Orphan Europe SARL Immeuble “Le Wilson”
Orphan Europe S.A.R.L Immeuble "Le Wilson"
Orphan Europe SARL Immeuble “Le Wilson”
Orphan Europe SARL, Immeuble “Le Wilson”
Orphan Europe SARL Tel: +33 1 47 73 64 58
Orphan Europe SARL Tél : +33 1 47 73 64 58
Orphan Europe SARL Tél: +33 (0)1 47 73 64 58
Orphan Europe SARL Tel. : +33 1 47 73 64 58
Orphan Europe SARL Tél: +33 (0)1 47 73 64 58
Orphan Europe SARL Tél. : +33 1 47 73 64 58
Orphan Europe SARL Τηλ : +33 1 47 73 64 58
Orphan Europe SARL Tél : +33 1 47 73 64 58
Orphan Europe SARL Τηλ: +33 1 47 73 64 58
Orphan Europe SARL Tél : +33 1 47 73 64 58
ORR (95% CI) (%)
ORR (95 % CI) (%)
ORR (95% CI) by tumour PD-L1 expression level
ORR (95% CI) prema razini tumorske ekspresije PD-L1
ORR (all subjects)* 95% CI
ORR (svi ispitanici)* 95% CI
ORR (CR, Cru, and PR)
ORR (CR, CRu, i PR)
ORR (follicular lymphoma)* 95% CI
ORR (folikularni limfom)* 95% CI
ORR (partial responses only) (95% CI)
ORR (samo parcijalni odgovori) (95 % CI)
ORR and the duration of response were also assessed.
Ocjenjivali su se i ORR te trajanje odgovora.